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INTRODUCTION
Immunoglobulin G4 (IgG4)-related disease is a recently 
established clinical entity characterized by infiltration or 
mass formation with IgG4-producing plasma cells and lym-
phocytes often accompanied by fibrosis in multiple organs.1 
The 2011 comprehensive diagnostic criteria for IgG4-related 
disease in Japan were published by the Government-sponsored 
taskforce of Japanese clinicians and pathologists in January 
2012,2 and the measurement of serum IgG4 became covered 
by reimbursement of national health insurance in Japan in 
December 2012.   In January 2020, towards worldwide rec-
ognition of the entity, the 2019 classification criteria for 
IgG4-related disease were published by American College of 
Rheumatology and European League Against Rheumatism.3,4 
The pathological criteria remain key for the diagnosis of 
IgG4-related disease and an increase in serum IgG4 levels 
supports the clinical diagnosis.5
In the field of ophthalmology, the diagnostic criteria for 
IgG4-related ophthalmic disease were published in 2015,6 
together with the criteria in other organs such as autoimmune 
pancreatitis and sclerosing cholangitis.   We previously 
reported a series of patients with IgG4-related disease in the 
ocular adnexa in 20107 and demonstrated IgG4-related dis-
ease in the background of extranodal marginal zone B-cell 
lymphoma of mucosa-associated lymphoid tissue (MALT 
lymphoma) in the lacrimal gland in 2011.8   In this study, we 
reviewed an additional series of patients with IgG4-related 
disease diagnosed in the lacrimal gland and examined their 
follow-up by monitoring serum IgG4 levels in the era after 
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the establishment of the diagnostic criteria.   The clinical 
question in this study was whether serum IgG4-monitoring 
aided in deciding the treatment for IgG4-related disease.
METHODS
Eight consecutive patients with lacrimal gland lesions 
who were diagnosed with IgG4-related disease between 2009 
and 2020 were retrospectively reviewed (Table 1).   Case 1 in 
this study was reported in part as Case 9 in our previous 
study,7 and Case 2 was reported in our previous case report.8 
The follow-up of these two patients is described in this study. 
The study was performed according to the Declaration of 
Helsinki and was approved as a retrospective study by the 
ethics committee of Okayama University Graduate School of 
Medicine, Dentistry, and Pharmaceutical Sciences and 
Okayama University Hospital.   All 8 patients, except one 
(Case 5) who declined surgery, underwent excisional biopsy 
of the lacrimal gland lesions by a single surgeon (TM) at 
Okayama University Hospital and were diagnosed with 
IgG4-related disease by immunostaining of paraffin sections 
at the Department of Pathology.
Data collected from medical records were gender, age at 
the initial presentation and surgery, laterality of lacrimal 
gland involvement, pathological findings, prednisolone treat-
ment, follow-up period, serum IgG4 and soluble interleu-
kin-2 receptor (sIL-2R) levels at each visit, magnetic reso-
nance imaging and whole-body 2-[18F]fluoro-2-deoxy-D-
glucose positron emission tomography (FDG-PET) findings, 
and systemic signs other than orbital signs throughout the 
course.
Immunohistochemical staining was based on the protocol 
recommended for the Bond Polymer Refine Detection Kit in 
the Bond-III Fully Automated IHC and ISH Stainer system 
(Leica Biosystems, Welzlar, Germany).   Primary antibodies 
used were: mouse monoclonal antibodies against CD3 (Leica 
NCL-L-CD3-565, Leica Biosystems Novocastra), CD20 
(Leica NCL-L-CD20-L26), IgG4 (MBL BS-MCO11, 
Medical & Biological Laboratories, Nagoya), and IgG (Leica 
NCL-L-IgG).   Both κ light chain and λ light chain were 
detected by in situ hybridization using Bond Ready-to-Use 




The 8 patients comprised 3 men and 5 women ranging in 
age from 52 to 77 (median, 63) years at the initial visit to the 
Department of Ophthalmology (Table 1).   The follow-up 
period ranged from 0.25 to 11 (median, 7) years.   Bilateral 
and unilateral involvement was noted in 4 patients each: 2 on 
the right side and 2 on the left side in those with unilateral 
involvement (Fig. 1, Fig. 2).   Excisional biopsy was sched-
uled within one month after the initial visit for 7 patients. 
The 4 patients with bilateral lacrimal gland lesions underwent 
bilateral excisional biopsy.   Histopathology with immunos-
taining confirmed IgG4-related disease in the lacrimal gland 
lesions.   One patient (Case 5) declined excisional biopsy. 
The clinical diagnosis in this patient was thus based on the 
increase in serum IgG4, and clinical exclusion of lymphoma 
and sarcoidosis in the course of the disease.
The serum IgG4 level was high in 5 of 8 patients at the 
initial visit based on the diagnostic criteria of 135 mg/dL or 
higher (Table 1).   The serum sIL-2R level was high in 5 of 8 
patients at the initial visit.   During follow-up, 7 of the 8 
patients exhibited a relative increase in serum IgG4 at the last 
visit compared with the initial visit (Fig. 3).   The serum 
IgG4 level decreased after surgery in only two patients 
(Cases 7 and 8, Fig. 3).   Another patient (Case 5) with no 
surgery also had a decrease in serum IgG4 in response to oral 
prednisolone (Fig. 3) compared with the level at the initial 
visit.   Five patients with no systemic signs were followed 
without treatment.   In contrast, oral prednisolone at an initial 
dose ranging from 10 to 30 mg daily was administered to the 
other 3 patients (Cases 4, 5, and 7) who exhibited systemic 
signs on FDG-PET and later tapered.   The systemic signs 
were prostatic and lung lesions in Case 4, mediastinal lesions 
(Fig. 1I) in Case 5, and pancreatic (Fig. 2H) and bilateral 
submandibular gland lesions (Fig. 2G) in Case 7.   The lacri-
mal gland mass and mediastinal lesions resolved in response 
to oral prednisolone in one patient (Case 5) without a patho-
logical diagnosis.
The patient (Case 2) with a history of radiation therapy 
for MALT lymphoma in the bilateral lacrimal glands devel-
oped IgG4-related disease (Fig. 1C, 1D) in the left lacrimal 
gland 10 years later and was followed without treatment after 
the pathological diagnosis of IgG4-related disease (Fig. 
4A-4F).8   Nine years after the diagnosis of lacrimal gland 
IgG4-related disease by the second excisional biopsy, her 
serum IgG4 level increased to 2090 mg/dL (Fig. 3), and para-
cardiac lesions were found by FDG-PET (Fig. 1E, 1F) and 
confirmed to be MALT lymphoma by needle biopsy (Fig. 
4G-4L).   In half a year, she underwent 5 courses of benda-
mustine (90 mg/m2 on days 1 and 2) combined with ritux-
imab (375 mg/m2 on day 1) as systemic chemotherapy to 
achieve complete remission.   She received oral mesalazine at 
2400 mg daily throughout the course.   At the final visit, half 
a year after chemotherapy, the serum IgG4 level decreased to 
155 mg/dL from the highest value of 2090 mg/dL (Fig. 3) 
and serum sIL-2R level decreased to 438 U/mL from the 
highest value of 1527 U/mL.   The other 7 patients did not 
have local recurrence or additional systemic signs.
Pathological findings
Lacrimal gland lesions in all 7 patients with excisional 
biopsy fulfilled the pathological criteria of IgG4-related dis-
ease: 10 or more IgG4-positive cells in a high-power field 
and 40% or higher ratio of IgG4-positive cells over IgG-
positive cells (Table 1).   In Case 2 with later development of 
paracardiac MALT lymphoma, the left lacrimal gland lesion 
diagnosed as IgG4-related disease contained lymphoid folli-
cles with interfollicular fibrotic bundles (Fig. 4A, 4B), and 
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Fig. 1. Case 1. Bilateral lacrimal gland masses on magnetic resonance imaging (A) and high uptake by the bilat-
eral lacrimal glands on gallium-67 scintigraphy (B). Case 2. Left lacrimal gland mass on magnetic resonance 
imaging (arrow, C) and high uptake by the lacrimal gland mass on whole-body 2-[18F]fluoro-2-deoxy-D-glucose 
positron emission tomography (FDG-PET) (arrow, D). Paracardiac lesions on computed tomography (E) and high 
uptake on FDG-PET (arrows, F). Case 5. Right lacrimal gland mass on magnetic resonance imaging (G), and high 
uptake on FDG-PET by the right lacrimal gland (arrow, H) and mediastinal lesion (arrow, I).
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Fig. 2. Case 3. Bilateral lacrimal gland masses on magnetic resonance imaging (A). Case 4. Left lacrimal gland 
mass on magnetic resonance imaging (B). Case 6. Bilateral lacrimal gland masses on magnetic resonance imaging 
(C) and weak uptake by bilateral lacrimal gland masses on whole-body 2-[18F]fluoro-2-deoxy-D-glucose positron 
emission tomography (FDG-PET) (D). Case 7. Right lacrimal gland mass on magnetic resonance imaging (E) and 
high uptake on FDG-PET by the right lacrimal gland mass (F). High uptake on FDG-PET by bilateral submandib-
ular glands (arrow, G) and the pancreas (arrow, H). Case 8. Bilateral lacrimal gland masses on magnetic resonance 
imaging (I) and granular shadows in the lung field (J).
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was infiltrated by plasma cells and lymphocytes.   The ratio 
of IgG4/IgG-positive cells (Fig. 4C, 4D) was 100%, and κ 
light chain-positive cells (Fig. 4E) and λ light chain-positive 
cells (Fig. 4F) were similar in number.   In contrast, the para-
cardiac lesion diagnosed as MALT lymphoma exhibited dif-
fuse infiltration with medium-sized lymphoid cells (Fig. 4G, 
4H).   The ratio of IgG4/IgG-positive cells (Fig. 4I, 4J) was 
30%, and κ light chain-positive cells (Fig. 4K) were more 
predominant than λ light chain-positive cells (Fig. 4L). 
IgG4-positive cells appeared as lymphoma cells because they 
overlapped with predominant κ light chain-positive cells.
In Case 2, left and right lacrimal gland lesions diagnosed 
as MALT lymphoma 10 and 7 years previously, respectively, 
before the diagnosis of IgG4-related disease in the left lacri-
mal gland, were reexamined by novel immunostaining (Fig. 
5).   The paraffin block containing the right lacrimal gland 
tissue was sufficiently large for re-sectioning to stain IgG, 
IgG4, κ light chain, and λ light chain (Fig. 5E-5H), but only 
IgG4 (Fig. 5B) was stained on a preserved paraffin section of 
the left lacrimal gland tissue because little tissue in the paraf-
fin block remained after the previous sectioning.   In MALT 
lymphoma of the left lacrimal gland 10 years previously, the 
number of IgG4-positive cells was 10 or greater in a high-
power field (Fig. 5B).   In MALT lymphoma of the right lac-
rimal gland 7 years previously, IgG-positive cells (Fig. 5E) 
were present in a small number, but IgG4-positive cells (Fig. 
5F) were absent.   In the lesion of the right lacrimal gland, κ 
light chain-positive cells (Fig. 5G) were more predominant 
than λ light chain-positive cells (Fig. 5H), which was consistent 
with κ chain predominance in the paracardiac lesion (Fig. 
4K).
In 4 patients with bilateral lacrimal gland involvement 
with IgG4-related disease, the extent of fibrosis was basically 
the same between the bilateral lesions in 3 patients, whereas 
extent of fibrosis differed between the right-side and left-side 
lesions in the remaining one patient (Case 6).   In Case 3 with 
a serum IgG4 level of 432 mg/dL, the extent of fibrosis was 
similar between the lesions on the right side (Fig. 6A-6D) 
and the left side (Fig. 6E-6H).   In contrast, fibrosis was more 
marked in the right-side lesion (Fig. 7A-7D) than in the left-
side lesion with better preservation of lacrimal gland acini 
(Fig. 7E-7H) in Case 6 with no increase in the serum IgG4 
level at 40 mg/dL.   In all lesions of the 7 patients who under-
went excisional biopsy, IgG4-positive cells were found 
mainly in interfollicular spaces (Fig. 6D, 6H) and among lac-
rimal gland acini (Fig. 7H).   There was also a small number 
of IgG4-positive cells infiltrating the follicles (Fig. 6H).
DISCUSSION
The clinical question in this study was the utility of 
serum IgG4-monitoring in follow-up of patients diagnosed 
with IgG4-related disease based on the lacrimal gland lesions 
in the era of the established disease criteria.   Since the estab-
lishment of the comprehensive diagnostic criteria of IgG4-
related disease,2 there have been several reports of series of 
Fig. 3. Serum IgG4 levels during the follow-up periods of 8 patients. Measured values are shown as closed circles. The period with 
missing data in Case 2 is shown by a broken line. Zero point on the horizontal line (years) indicates the timing for excisional biopsy in all 
cases except for Case 5 without surgery at the initial visit. Case 8 had only two measurements in a short follow-up period of 3 months.
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patients with IgG4-related disease in the ocular adnexa, so-
called IgG4-related ophthalmic disease.9-13   The measurement 
of serum IgG4 may be used to detect relapse after predniso-
lone treatment in the follow-up of patients with pathologi-
cally confirmed IgG4-related ophthalmic disease.13   In the 
present series of patients, serum IgG4 levels were monitored 
but not used as a guide for adjusting the dose of oral prednis-
olone in 3 patients with steroid therapy.   The presence of 
symptoms and signs, revealed mainly by computed tomogra-
phy, in addition to adverse events caused by prednisolone, 
were used to determine the tapering and discontinuation of 
prednisolone in these patients.
Lacrimal gland masses must be differentiated from 
inflammation and malignancy.   Lymphoma is frequent in the 
lacrimal gland14-17 compared with epithelial tumors such as 
benign and malignant pleomorphic adenoma.   An increase in 
the serum sIL-2R level, as measured in the present series of 
patients, supports lymphoproliferative disorders, such as lym-
phoma, and sarcoidosis.   IgG4-related disease is a common 
cause of inflammatory diseases in the lacrimal gland.   In 
Fig. 4. Case 2. IgG4-related disease in the left lacrimal gland mass (A-F). Lymphoid follicles separated by fibrotic 
bundles (A), and infiltration of plasma cells and lymphocytes (B). IgG4 (D) / IgG (C) = 100%. κ chain (E) and λ 
chain (F) bitype. MALT lymphoma in a paracardiac mass (G-L). Diffuse infiltration of medium-sized lymphoid 
cells in the needle biopsy specimen (G, H). IgG4 (J) / IgG (I) = 30%. Dominant κ chain (K) in comparison with λ 
chain (L). White scale bar = 500 µm in A, bar = 100 µm in B-F, bar =200 µm in G, and bar = 50 µm in H-L.
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Fig. 5. Case 2. Re-immunostaining of left (A, B) and right (C-H) lacrimal gland lesions diagnosed as MALT 
lymphoma 10 and 7 years previously, respectively, from the time point of diagnosis of IgG4-related disease in the 
left lacrimal gland mass. Obscured follicular structure, and diffuse infiltration of medium-sized lymphoid cells on 
the left (A) and right sides (C, D). IgG4-positive cells are present (B) on the left side. IgG-positive cells are pres-
ent (E) but IgG4-positive cells are absent (F) on the right side. Note dominant κ chain (G) in comparison with λ 
chain (H) on the right side. White scale bar = 200 µm in A, bar = 50 µm in B, bar =500 µm in C, and bar = 100 
µm in D-H.
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Fig. 6. Case 3. Lacrimal gland masses on the right (A-D) and left sides (E-H). Lymphoid follicles separated 
by fibrotic bundles (A, E), and infiltration of plasma cells and lymphocytes (B, F). Note lacrimal gland acini in 
F. IgG4 (D) / IgG (C) = 90% on the right side and IgG4 (H) / IgG (G) = 50% on the left side. White scale bar 
= 500 µm in A and E, bar = 100 µm in B-D and F-H.
18
Serum IgG4 monitoring
Fig. 7. Case 6. Lacrimal gland masses on the right (A-D) and left sides (E-H). Lymphoid follicles separated 
by fibrotic bundles (A), and infiltration of plasma cells and lymphocytes (B, F). Note less fibrotic change and 
preservation of lacrimal gland acini on the left side (E, F). IgG4 (D) / IgG (C) = 100% on the right side and 
IgG4 (H) / IgG (G) = 100% on the left side. White scale bar = 500 µm in A and E, bar = 100 µm in B-D and 
F-H.
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addition, sarcoidosis and Kimura disease18 have to be consid-
ered as other causes of inflammation in the lacrimal gland. 
There is also the entity of idiopathic orbital inflammation or 
orbital pseudotumor with non-specific inflammation, which 
does not satisfy the pathological criteria of IgG4-related dis-
ease.19   Furthermore, MALT lymphoma can develop in the 
background of IgG4-related disease in the lacrimal gland.20,21 
The above strongly suggest that pathological diagnosis by 
biopsy is required in the case of lacrimal gland masses.
In the present series of patients, 3 (Cases 1, 4, and 6) did 
not fulfill the serum IgG4 level criteria of 135 mg/dL or 
higher at the initial visit.   Indeed, all 7 patients with exci-
sional biopsy demonstrated a typical pathology pattern for 
IgG4-related disease.   There was no difference in pathologi-
cal findings between the patients with and without an 
increase in serum IgG4 based on the diagnostic criteria. 
Furthermore, the presence of other systemic signs was unable 
to explain the higher serum IgG4 levels at the initial visit.   In 
addition, oral prednisolone, which was prescribed to 3 
patients (Cases 4, 5, and 7), did not necessarily lead to a sta-
ble reduction of serum IgG4 levels (Fig. 3).   Therefore, 
regarding the clinical question in this study, it remains 
unclear whether serum IgG4 levels can be used to monitor 
the disease activity and systemic involvement of IgG4-
related disease.
All 7 patients (Cases 1-7) in the present study with long-
term follow-up, except for one (Case 1), exhibited a relative 
increase in serum IgG4 levels at the last visit compared with 
the initial visit, irrespective of prednisolone treatment.   They 
did not have novel symptoms or signs on computed tomogra-
phy or FDG-PET.   As an exception, one patient (Case 2) 
with markedly high serum IgG4 levels over 1500 mg/dL had 
high-uptake lesions in the paracardiac area and was con-
firmed to have MALT lymphoma by biopsy.   This patient 
had a low level of serum IgG4 at the last visit after systemic 
chemotherapy for MALT lymphoma.   Overall, a relative 
increase in serum IgG4 levels over time is acceptable except 
for excessive increases over 1500 mg/dL.   In the last patient 
(Case 8) with a short follow-up period (3 months), the 
increase in serum IgG4 at the initial visit supported IgG4-
related disease as a probable cause for elastic-hard bilateral 
lacrimal gland masses.
In the sequence of events in Case 2, the patient first 
developed left lacrimal gland MALT lymphoma with λ light 
chain predominance and positive IgG4.   Three years later, 
she developed right lacrimal gland MALT lymphoma with κ 
light chain predominance and negative IgG4, and left lacri-
mal gland IgG4-related disease with κ and λ chain bitype 7 
years after that.8   Nine years later, she developed paracardic 
MALT lymphoma with κ light chain predominance and posi-
tive IgG4.   Re-staining of the preceding MALT lymphomas 
confirmed that IgG4-positive cells were present in the left 
lacrimal gland lesion 10 years previously but absent in the 
right lacrimal gland lesion 7 years prior to the time point of 
the diagnosis of IgG4-related disease in the left lacrimal 
gland.8   Subsequently, IgG4-positive cells were present in a 
large number in the paracardiac lesion of MALT lymphoma 9 
years after the diagnosis of IgG4-related disease in the left 
lacrimal gland.   The shared κ light chain predominance sug-
gests the same lineage of lymphoma cells in the preceding 
and later MALT lymphoma in different sites of the body. 
The increase in IgG4-positive cells in the later paracardiac 
lesion of MALT lymphoma may have played a role in the 
relapse of lymphoma, regardless of whether lymphoma cells 
produced IgG4.22
A major limitation in this retrospective study was that 
serum IgG4 measurements were not performed at each visit 
throughout the follow-up period.   In Case 2, serum IgG4 
data were missing for a long period after the initial measure-
ment at excisional biopsy with the diagnosis of IgG4-related 
disease because the patient had ulcerative colitis and was fol-
lowed by an internist at another hospital.   The second limita-
tion is that the present study included only patients with 
IgG4-related disease in lacrimal glands.   Serum IgG4 moni-
toring, therefore, cannot be generalized to IgG4-related dis-
ease in other organs such as autoimmune pancreatitis.   Even 
with these limitations, follow-up with serum IgG4 monitor-
ing may be useful to detect new lymphoma in patients with 
IgG4-related disease when the serum IgG4 level markedly 
increases during the time course of IgG4-related disease in 
the lacrimal gland.
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